CLIMB BIO, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
CLIMB BIO, INC. (CLYM) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2023-03-06
- CLIMB BIO, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00.
- CLIMB BIO, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- CLIMB BIO, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-06-30 was $0.00.
- CLIMB BIO, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-03-31 was $0.00.
- CLIMB BIO, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2022 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |